398 related articles for article (PubMed ID: 31563999)
21. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
[TBL] [Abstract][Full Text] [Related]
22. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
23. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
24. Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy.
Si J; Shao S; Shen Y; Wang K
Small; 2016 Oct; 12(37):5108-5119. PubMed ID: 27560388
[TBL] [Abstract][Full Text] [Related]
25. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
26. Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment.
Hameedat F; Pizarroso NA; Teixeira N; Pinto S; Sarmento B
Eur J Pharm Sci; 2022 Sep; 176():106259. PubMed ID: 35842140
[TBL] [Abstract][Full Text] [Related]
27. Surface engineered multifunctional nano-systems for localised drug delivery against thyroid cancer: A review of current practices.
Zhang Y; Tang N; Zhou H; Zhu Y
Biomed Pharmacother; 2024 Jul; 176():116840. PubMed ID: 38820975
[TBL] [Abstract][Full Text] [Related]
28. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
29. Bioinspired and Biomimetic Nanomedicines.
Chen Z; Wang Z; Gu Z
Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
[TBL] [Abstract][Full Text] [Related]
30. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer.
Van Cutsem E
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S60-5. PubMed ID: 18021489
[TBL] [Abstract][Full Text] [Related]
31. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Linton SS; Sherwood SG; Drews KC; Kester M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
[TBL] [Abstract][Full Text] [Related]
32. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
Koning GA; Krijger GC
Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
[TBL] [Abstract][Full Text] [Related]
33. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
35. High drug-loading nanomedicines: progress, current status, and prospects.
Shen S; Wu Y; Liu Y; Wu D
Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349
[TBL] [Abstract][Full Text] [Related]
38. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
[TBL] [Abstract][Full Text] [Related]
39. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
[TBL] [Abstract][Full Text] [Related]
40. Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.
Battistella C; Klok HA
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28444959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
